ALDX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Aldeyra The

NASDAQ | ALDX

5.24

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 24, 2025)

$311.04M

Market Cap

-

P/E Ratio

-0.85

EPS

$7.20

52 Week High

$1.13

52 Week Low

HEALTHCARE

Sector

ALDX Chart

Recent Chart
Price Action

ALDX Technicals

Tags:

ALDX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$250K
Total Revenue $0
Cost Of Revenue $250K
Costof Goods And Services Sold $250K
Operating Income -$60M
Selling General And Administrative $12M
Research And Development $48M
Operating Expenses $60M
Investment Income Net -
Net Interest Income $4.3M
Interest Income $6.2M
Interest Expense $1.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $250K
Income Before Tax -$56M
Income Tax Expense -$56T
Interest And Debt Expense -
Net Income From Continuing Operations -$56M
Comprehensive Income Net Of Tax -
Ebit -$54M
Ebitda -$54M
Net Income -$56M

Revenue & Profitability

Earnings Performance

ALDX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $105M
Total Current Assets $104M
Cash And Cash Equivalents At Carrying Value $55M
Cash And Short Term Investments $55M
Inventory -
Current Net Receivables -
Total Non Current Assets $534K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $47M
Other Current Assets $2.9M
Other Non Current Assets -
Total Liabilities $34M
Total Current Liabilities $19M
Current Accounts Payable $180K
Deferred Revenue -
Current Debt -
Short Term Debt $303K
Total Non Current Liabilities $15M
Capital Lease Obligations $272K
Long Term Debt $15M
Current Long Term Debt $31K
Long Term Debt Noncurrent -
Short Long Term Debt Total $15M
Other Current Liabilities $12M
Other Non Current Liabilities -
Total Shareholder Equity $71M
Treasury Stock -
Retained Earnings -$450M
Common Stock $60K
Common Stock Shares Outstanding $59M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$43M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $250K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$45M
Cashflow From Financing -$171K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$56M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$250K
Total Revenue $0
Cost Of Revenue $250K
Costof Goods And Services Sold $250K
Operating Income -$60M
Selling General And Administrative $12M
Research And Development $48M
Operating Expenses $60M
Investment Income Net -
Net Interest Income $4.3M
Interest Income $6.2M
Interest Expense $1.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $250K
Income Before Tax -$56M
Income Tax Expense -$56T
Interest And Debt Expense -
Net Income From Continuing Operations -$56M
Comprehensive Income Net Of Tax -
Ebit -$54M
Ebitda -$54M
Net Income -$56M

ALDX News

ALDX Profile

Aldeyra The Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Aldeyra Therapeutics, Inc. is a biotechnology firm based in Lexington, Massachusetts, focused on advancing innovative therapies for immune-mediated systemic conditions and ocular diseases. With a robust pipeline of product candidates utilizing its proprietary platform, the company is dedicated to addressing significant unmet medical needs in therapeutic domains including corneal health and systemic autoimmune disorders. Aldeyra's commitment to research and development, coupled with its strategic collaborations, positions it for sustainable growth and potential breakthroughs in the biopharmaceutical landscape.

BYND
-23.06%
$2.18
WGRX
+185.43%
$1.14
VHAI
-50.00%
$0.00
TOVX
+0.87%
$0.34
YYAI
-14.98%
$0.07
VIVK
+11.91%
$0.29
F
+12.15%
$13.84
YDKG
-15.04%
$0.06
ASST
+27.28%
$1.10
INTC
+0.31%
$38.28
BURU
+17.26%
$0.40
CENN
-0.74%
$0.21
DVLT
+52.00%
$3.42
CGBS
-39.47%
$0.03
NVDA
+2.25%
$186.26
BITF
+10.68%
$4.61
TSLA
-3.39%
$433.72
AAL
+7.90%
$13.78
DNN
+2.93%
$2.81
CJET
+27.98%
$0.11
RGTI
-1.90%
$38.84
NEUP
+54.07%
$6.24
ADTX
-28.06%
$0.21
PLUG
+2.43%
$2.95
T
+2.11%
$25.14
RIG
+0.25%
$3.90
SCNX
-39.61%
$1.57
NOK
+2.10%
$6.30
AMD
+7.63%
$252.92
QBTS
+5.11%
$32.65
AXDX
-61.36%
$0.03
ABEV
-0.90%
$2.19
GPUS
+4.19%
$0.40
WTO
-7.14%
$0.06
RF
+1.95%
$24.57
CAN
+7.38%
$1.89
LAES
+22.55%
$7.01
SOFI
+3.31%
$29.01
NEHC
+48.35%
$5.86
NUAI
+48.35%
$5.86
QLGN
+3.11%
$3.64
ONDS
+5.66%
$7.46
GRAB
+2.27%
$5.85
TLRY
+0.67%
$1.49
QS
+14.73%
$16.82
ADAP
-7.57%
$0.06
SNAP
+1.01%
$7.95
CIFR
+19.73%
$20.66
AIRE
-22.42%
$0.76
ETHD
-3.52%
$3.83
JOBY
+2.93%
$16.13
ACHR
+3.48%
$11.29
IONZ
-4.02%
$3.82
RMBL
+60.50%
$3.21
RXRX
+5.41%
$6.04
BAC
+1.56%
$52.57
AMZN
+1.41%
$224.21
NIO
+0.14%
$6.90
AAPL
+1.24%
$262.82
ADD
-25.47%
$0.05
QUBT
-2.57%
$15.53
IREN
+12.60%
$62.90
BTBT
+5.10%
$3.91
RR
+12.17%
$6.08
AMC
-1.46%
$2.69
NVTS
+3.37%
$14.07
SRM
+53.27%
$10.30
PLTR
+2.29%
$184.63
CLOV
+19.37%
$3.82
UUUU
+0.51%
$21.37
BTG
-0.38%
$5.21
DFLI
+13.27%
$1.28
RVPH
+18.99%
$0.67
BBD
0.00%
$3.35
MARA
+1.66%
$19.54
NAKA
+5.66%
$0.84
KDLY
+5.66%
$0.84
APLD
+0.14%
$33.43
CUTR
-10.19%
$0.09
PBR
-0.84%
$11.74
WU
+10.19%
$8.97
GOOGL
+2.70%
$259.92
SOUN
-1.42%
$17.98
WLGS
-5.57%
$0.04
RIVN
-0.84%
$12.98
IONQ
+1.56%
$60.30
VZ
+1.09%
$38.82
PFE
+0.36%
$24.76
WULF
+6.44%
$13.71
LAZR
+31.36%
$2.22
ETWO
0.00%
$3.30
RGTZ
+3.08%
$15.36
SKYQ
+9.15%
$0.50
MU
+5.95%
$219.02
JBLU
0.00%
$4.57
SMCI
+0.77%
$48.29
CLSK
+9.59%
$19.36
WBD
-0.47%
$21.15
LUMN
+3.85%
$8.09
HOOD
+4.06%
$139.79
BYND
-23.06%
$2.18
WGRX
+185.43%
$1.14
VHAI
-50.00%
$0.00
TOVX
+0.87%
$0.34
YYAI
-14.98%
$0.07
VIVK
+11.91%
$0.29
F
+12.15%
$13.84
YDKG
-15.04%
$0.06
ASST
+27.28%
$1.10
INTC
+0.31%
$38.28
BURU
+17.26%
$0.40
CENN
-0.74%
$0.21
DVLT
+52.00%
$3.42
CGBS
-39.47%
$0.03
NVDA
+2.25%
$186.26
BITF
+10.68%
$4.61
TSLA
-3.39%
$433.72
AAL
+7.90%
$13.78
DNN
+2.93%
$2.81
CJET
+27.98%
$0.11
RGTI
-1.90%
$38.84
NEUP
+54.07%
$6.24
ADTX
-28.06%
$0.21
PLUG
+2.43%
$2.95
T
+2.11%
$25.14
RIG
+0.25%
$3.90
SCNX
-39.61%
$1.57
NOK
+2.10%
$6.30
AMD
+7.63%
$252.92
QBTS
+5.11%
$32.65
AXDX
-61.36%
$0.03
ABEV
-0.90%
$2.19
GPUS
+4.19%
$0.40
WTO
-7.14%
$0.06
RF
+1.95%
$24.57
CAN
+7.38%
$1.89
LAES
+22.55%
$7.01
SOFI
+3.31%
$29.01
NEHC
+48.35%
$5.86
NUAI
+48.35%
$5.86
QLGN
+3.11%
$3.64
ONDS
+5.66%
$7.46
GRAB
+2.27%
$5.85
TLRY
+0.67%
$1.49
QS
+14.73%
$16.82
ADAP
-7.57%
$0.06
SNAP
+1.01%
$7.95
CIFR
+19.73%
$20.66
AIRE
-22.42%
$0.76
ETHD
-3.52%
$3.83
JOBY
+2.93%
$16.13
ACHR
+3.48%
$11.29
IONZ
-4.02%
$3.82
RMBL
+60.50%
$3.21
RXRX
+5.41%
$6.04
BAC
+1.56%
$52.57
AMZN
+1.41%
$224.21
NIO
+0.14%
$6.90
AAPL
+1.24%
$262.82
ADD
-25.47%
$0.05
QUBT
-2.57%
$15.53
IREN
+12.60%
$62.90
BTBT
+5.10%
$3.91
RR
+12.17%
$6.08
AMC
-1.46%
$2.69
NVTS
+3.37%
$14.07
SRM
+53.27%
$10.30
PLTR
+2.29%
$184.63
CLOV
+19.37%
$3.82
UUUU
+0.51%
$21.37
BTG
-0.38%
$5.21
DFLI
+13.27%
$1.28
RVPH
+18.99%
$0.67
BBD
0.00%
$3.35
MARA
+1.66%
$19.54
NAKA
+5.66%
$0.84
KDLY
+5.66%
$0.84
APLD
+0.14%
$33.43
CUTR
-10.19%
$0.09
PBR
-0.84%
$11.74
WU
+10.19%
$8.97
GOOGL
+2.70%
$259.92
SOUN
-1.42%
$17.98
WLGS
-5.57%
$0.04
RIVN
-0.84%
$12.98
IONQ
+1.56%
$60.30
VZ
+1.09%
$38.82
PFE
+0.36%
$24.76
WULF
+6.44%
$13.71
LAZR
+31.36%
$2.22
ETWO
0.00%
$3.30
RGTZ
+3.08%
$15.36
SKYQ
+9.15%
$0.50
MU
+5.95%
$219.02
JBLU
0.00%
$4.57
SMCI
+0.77%
$48.29
CLSK
+9.59%
$19.36
WBD
-0.47%
$21.15
LUMN
+3.85%
$8.09
HOOD
+4.06%
$139.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.